TY - JOUR
T1 - The difficulty in selecting patients for cytoreductive nephrectomy
T2 - An evaluation of previously described predictive models
AU - Manley, Brandon J.
AU - Tennenbaum, Daniel M.
AU - Vertosick, Emily A.
AU - Hsieh, James J.
AU - Sjoberg, Daniel D.
AU - Assel, Melissa
AU - Benfante, Nicole E.
AU - Strope, Seth A.
AU - Kim, Eric
AU - Casuscelli, Jozefina
AU - Becerra, Maria F.
AU - Coleman, Jonathan A.
AU - Hakimi, Abraham Ari
AU - Russo, Paul
N1 - Publisher Copyright:
© 2017 Elsevier Inc.
PY - 2017/1/1
Y1 - 2017/1/1
N2 - Purpose To externally evaluate a preoperative points system and a preoperative nomogram, both created to assess time to death after cytoreductive nephrectomy (CN). Materials and methods We identified 298 patients who underwent CN at our institution, a tertiary cancer center, between 1989 and 2015. To validate the points system, we compared reported overall survival (OS) for each criterion to observed OS in our cohort. To evaluate the nomogram, we prognosticated risk of death at 6 months after surgery for 280 patients with sufficient follow-up in our cohort and evaluated discrimination using area under the curve (AUC) and calibration. Decision curve analysis was performed to assess clinical utility of the nomogram. Results Significant differences in OS were observed between patients with and without 5 of 7 criteria on univariate analysis: low albumin (P<0.0001), high lactate dehydrogenase (P = 0.002), liver metastasis (P = 0.004), retroperitoneal lymphadenopathy (P = 0.002), and supradiaphragmatic lymphadenopathy (P = 0.019). Discrimination from the preoperative model, predicting death within 6 months of surgery was lower in our cohort (AUC = 0.65, 95% CI: 0.52–0.79) than the original publication (AUC = 0.76). Decision curve analysis demonstrated little benefit for applicability. Conclusions Five previously defined risk factors are predictive of decreased OS after CN in our cohort. We found lower discrimination using the preoperative model and minimal clinical utility according to decision analysis in our study cohort. These findings suggest the need for improved models to aid patient stratification and consequent treatment choice.
AB - Purpose To externally evaluate a preoperative points system and a preoperative nomogram, both created to assess time to death after cytoreductive nephrectomy (CN). Materials and methods We identified 298 patients who underwent CN at our institution, a tertiary cancer center, between 1989 and 2015. To validate the points system, we compared reported overall survival (OS) for each criterion to observed OS in our cohort. To evaluate the nomogram, we prognosticated risk of death at 6 months after surgery for 280 patients with sufficient follow-up in our cohort and evaluated discrimination using area under the curve (AUC) and calibration. Decision curve analysis was performed to assess clinical utility of the nomogram. Results Significant differences in OS were observed between patients with and without 5 of 7 criteria on univariate analysis: low albumin (P<0.0001), high lactate dehydrogenase (P = 0.002), liver metastasis (P = 0.004), retroperitoneal lymphadenopathy (P = 0.002), and supradiaphragmatic lymphadenopathy (P = 0.019). Discrimination from the preoperative model, predicting death within 6 months of surgery was lower in our cohort (AUC = 0.65, 95% CI: 0.52–0.79) than the original publication (AUC = 0.76). Decision curve analysis demonstrated little benefit for applicability. Conclusions Five previously defined risk factors are predictive of decreased OS after CN in our cohort. We found lower discrimination using the preoperative model and minimal clinical utility according to decision analysis in our study cohort. These findings suggest the need for improved models to aid patient stratification and consequent treatment choice.
KW - Mortality
KW - Neoplasm metastasis
KW - Nephrectomy
KW - Prognosis
KW - Renal cell carcinoma
UR - http://www.scopus.com/inward/record.url?scp=84994175792&partnerID=8YFLogxK
U2 - 10.1016/j.urolonc.2016.07.010
DO - 10.1016/j.urolonc.2016.07.010
M3 - Article
C2 - 27567689
AN - SCOPUS:84994175792
SN - 1078-1439
VL - 35
SP - 35.e1-35.e5
JO - Urologic Oncology: Seminars and Original Investigations
JF - Urologic Oncology: Seminars and Original Investigations
IS - 1
ER -